Extended Data Fig. 2: Progression free survival and overall survival in matched historical control group and vaccine injection site reaction. | Nature Medicine

Extended Data Fig. 2: Progression free survival and overall survival in matched historical control group and vaccine injection site reaction.

From: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

Extended Data Fig. 2

a) Kaplan-Meier curve of progression free survival with corresponding 95% confidence intervals in the matched historical control group (n=74). Patients were matched on BRAF-status, PD-L1-status, age, gender, M-stage and LDH level). b) Kaplan-Meier curve of overall survival with corresponding 95% confidence intervals in the matched historical control group (n=74). c) Images of injection site reaction in patient MM20 (CR) after 11 vaccination show redness, rash and granuloma at injection site.

Back to article page